Last Updated: September 29, 2026

Patent: 10,167,492

✉ Email this page to a colleague

Summary for Patent: 10,167,492

Title:	Process for manipulating the level of glycan content of a glycoprotein
Abstract:	The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Inventor(s):	Daniel R. Leiske, Michael T. Trentalange
Assignee:	Amgen Inc
Application Number:	US15/529,950
Patent Claims:	see list of patent claims

Details for Patent 10,167,492

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	1-Jun-10	10,167,492	2035-12-01
Amgen Inc.	XGEVA	denosumab	Injection	125320	18-Nov-10	10,167,492	2035-12-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,167,492

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015355087	⤷ Start Trial
Australia	2020202302	⤷ Start Trial
Australia	2022200586	⤷ Start Trial
Australia	2024204313	⤷ Start Trial
Australia	2025223948	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.